home.aspx
 
EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...

Coloplast

SHARESHARESHARE
Coloplast develops products and services to make life easier for people with deeply personal and private medical conditions. These conditions are often associated with trauma and taboo. The more intimate the condition, the greater the requirement to come closer to customers, understand their world and develop solutions that are sensitive to their special needs. We call this Intimate Healthcare.
SHARESHARESHARE

RELATED NEWS


Blueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set it on course for regulatory filings – and a close race to market with rival Deciphera. Avapritinib is an oral inhibitor of KIT and PDGFRA kinases and is being developed for GIST and systemic mastocytosis (SM), two diseases that are linked to mutations in these enzymes. New data from its phase 1 NAVIGATOR trial showed activity across all lines of therapy for patients wit...

READ MORE

The Phase III MYSTIC trial is evaluating Imfinzi (durvalumab) as monotherapy and in combination with tremelimumab, versus platinum-based standard-of-care (SoC) chemotherapy in previously-untreated patients with metastatic (Stage IV) 1st-line non-small cell lung cancer (NSCLC). The drug giant had been expecting results in the first half of the year but said in a statement that “based on current predictions, the final analysis of overall survival (OS) is now expected in the second half of 20...
PHARMATIMES
READ MORE

Representative images of lungs treated with gene therapy vectors. The nuclei are in blue, alveolar type II cells in green and telomeres in red. Notice that lung cells treated with active telomerase present more intense telomeres indicating that they are longer as compared to lung cells treated with the null vectors or with an inactive telomerase. Credit: CNIO. Negative results and findings in science are perhaps less newsworthy, but they are no less important. Particularly when, as in this case,...

READ MORE

A new class of drugs to treat autoimmune diseases, diabetes, chronic pain and many other conditions could be made using venom. Venoms have been researched as potential medicinal agents for many years, with some snake, bee, and scorpion venoms having shown anti-tumour properties in previous studies in cell culture. Bee venom has also been used in many tribal areas in East Asia, with scorpion venom being used in traditional Chinese medicine....

READ MORE

It may not be what Takeda bargained for with its massive Shire buyout, but early into its ownership of the rare disease specialist, a jury ordered the Japanese drugmaker to pay hemophilia rival Bayer $155 million for patent infringement. The case dates back to a December 2016 lawsuit Bayer filed against Baxalta when the latter company was a unit of Shire. Now that Takeda has scooped up the Shire, it’ll be on the hook for the $155 million verdicts, which jurors ordered for Baxalta’s i...

READ MORE

If you eavesdropped in Lions Health’s Palais II headquarters Tuesday morning, you heard a lot of chatter about who picked up awards the night before, and even more speculation on why. Outside in its sprawling cabana, Facebook was handing out sodas, water and trail mix along with client case studies. But onstage and in session, it was about patient-first marketing, data-gathering, technology tools and why we’ll all be friends with robots by 2028.Meanwhile, speakers were talking up cha...
FIERCEPHARMA
READ MORE

EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...